STARTRK-2 for Advanced Solid Tumors with NTRK1/2/3, ROS1, or ALK Gene Rearrangements - Clinical Trial
What is the Purpose of this Study?
We are doing this study to learn if the study drug (entrectinib) is safe and will work in patients with advanced cancer with a gene mutation.
Solid tumor cancer with specific gene mutations
Who Can Participate in the Study?
Adults diagnosed with solid tumor cancer that has a gene mutation (NTRK1/2/3, ROS1, or ALK gene rearrangement).
What is Involved?
If you choose to be in this study you will:
- Have blood drawn, and a possible tumor tissue biopsy
- Physical and eye exam
- Complete quality of life surveys
- Take study drug (entrectinib) by mouth every day
- Take part in this study until your disease worsens or your study doctor requests you to stop